Cargando…

Circulating CD133(+)VEGFR2(+) and CD34(+)VEGFR2(+) cells and arterial function in patients with beta-thalassaemia major

Arterial dysfunction has been documented in patients with beta-thalassaemia major. This study aimed to determine the quantity and proliferative capacity of circulating CD133(+)VEGFR2(+) and CD34(+)VEGFR2(+) cells in patients with beta-thalassaemia major and those after haematopoietic stem cell trans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Yiu-fai, Chan, Shing, Yang, Mo, Ye, Jie-yu, Ha, Shau-yin, Wong, Sophia J., Chan, Godfrey Chi-fung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274669/ https://www.ncbi.nlm.nih.gov/pubmed/21808992 http://dx.doi.org/10.1007/s00277-011-1302-4

Ejemplares similares

Dynamic Dyssynchrony and Impaired Contractile Reserve of the Left Ventricle in Beta-Thalassaemia Major: An Exercise Echocardiographic Study
por: Cheung, Yiu-fai, et al.
Publicado: (2012)

Left ventricular torsional mechanics and myocardial iron load in beta-thalassaemia major: a potential role of titin degradation
por: Chen, Mei-pian, et al.
Publicado: (2014)

CD144, CD146 and VEGFR-2 properly identify circulating endothelial cell
por: Flores-Nascimento, Mariane Cristina, et al.
Publicado: (2015)

Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(−)CD45(+) cells during hepatocellular carcinoma progression
por: Zhu, Xiaolin, et al.
Publicado: (2017)

Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
por: Xu, Wen Wen, et al.
Publicado: (2014)

Native cardiac magnetic resonance T1 mapping and cardiac mechanics as assessed by speckle tracking echocardiography in patients with beta-thalassaemia major()
por: See, Wing-Shan, et al.
Publicado: (2021)

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
por: Farace, F, et al.
Publicado: (2011)

CD34(+)VEGFR-3(+) progenitor cells have a potential to differentiate towards lymphatic endothelial cells
por: Tan, Yu-zhen, et al.
Publicado: (2014)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

Enhancement of cardiac lymphangiogenesis by transplantation of CD34(+)VEGFR-3(+) endothelial progenitor cells and sustained release of VEGF-C
por: Zhang, Hai-feng, et al.
Publicado: (2019)

CD133 in brain tumor: the prognostic factor
por: Li, Bin, et al.
Publicado: (2016)

TBX1 Represses Vegfr2 Gene Expression and Enhances the Cardiac Fate of VEGFR2+ Cells
por: Lania, Gabriella, et al.
Publicado: (2015)

VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis
por: Virtej, Anca, et al.
Publicado: (2016)

EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF
por: Khayati, Farah, et al.
Publicado: (2015)

Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
por: Jinnin, Masatoshi, et al.
Publicado: (2008)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis
por: D'Haene, Nicky, et al.
Publicado: (2013)

Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex
por: Coon, Brian G., et al.
Publicado: (2015)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

Computational Modeling to Quantify the Contributions of VEGFR1, VEGFR2, and Lateral Inhibition in Sprouting Angiogenesis
por: Kühn, Clemens, et al.
Publicado: (2019)

VEGFR2 alteration in Alzheimer’s disease
por: Cho, Sun-Jung, et al.
Publicado: (2017)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Viability and intracellular nitric oxide generation in the umbilical cord blood CD34(+)CD133(–) and CD34(+)CD133(+) cell populations exposed to local anaesthetics
por: Kulińska, Karolina I., et al.
Publicado: (2021)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
por: Szabo, Emese, et al.
Publicado: (2016)

Circulating CD133+/–CD34– Have Increased c-MYC Expression in Myeloproliferative Neoplasms
por: Uslu Bıçak, İldeniz, et al.
Publicado: (2023)

Comprehensive Analysis of VEGFR2 Expression in HPV-Positive and -Negative OPSCC Reveals Differing VEGFR2 Expression Patterns
por: Uzun, Senem, et al.
Publicado: (2021)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
por: Bando, H, et al.
Publicado: (2005)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer
por: D’Haene, Nicky, et al.
Publicado: (2018)

VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis
por: Jang, Jeon Yeob, et al.
Publicado: (2017)

VEGFR2 trafficking: Speed doesn’t kill
por: Zhang, Xi, et al.
Publicado: (2013)

Microtubules Coordinate VEGFR2 Signaling and Sorting
por: Czeisler, Catherine, et al.
Publicado: (2013)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis
por: Durré, Tania, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g56mftfidtqaq7lr96bv4054d4